Literature DB >> 25742302

Correction: Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya.

.   

Abstract

Entities:  

Year:  2015        PMID: 25742302      PMCID: PMC4351063          DOI: 10.1371/journal.pone.0117761

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


× No keyword cloud information.
There are errors in Tables 1, 2, and 3 of the published article. Please view the corrected tables here.
Table 1

Baseline characteristics, perceived barriers and acceptance of the HPV vaccine; comparing respondents and non-respondents of the follow-up study.

TOTAL BASELINE (n = 287)FOLLOW-UP RESPONDENTS (n = 256)NON-RESPONDENTS (n = 31)
BASELINE CHARACTERISTICS
Median (IQR)Median (IQR)Median (IQR)p-value
Participant age at baseline35 (32–40)35 (32–40)35 (39–40)0.43
Range (years)21–5921–5923–56
Age of daughter at baseline12 (11–14)12 (11–14)12 (11–13)0.68
Range (years)8–188–188–17
Years of education of participant8 (7–12)8 (7–12)8 (6–11)0.35
Range (years)* 0–13+0–13+0–13+
Housing characteristics** 5 (4–5)5 (4–5)5 (4–6)0.04
Range1–72–73–7
n (%)n (%)n (%)p-value
Marital status of participant0.85
With partner217 (75.6)194 (75.8)23 (74.2)
Without partner70 (24.4)62 (24.2)8 (25.8)
Religious affiliation of participant0.48
Protestant226 (79.3)204 (80.3)22 (71.0)
Catholic46 (16.1)39 (15.3)7 (22.6)
Muslim13 (4.6)11 (4.3)2 (6.4)
Origin of participant*** 0.98
urban171 (60.2)153 (60.2)18 (60.0)
rural—outside Kenya113 (39.8)101 (39.8)12 (40.0)
Ever heard of cervical cancer?0.37
No—don’t know117 (40.9)102 (40.0)15 (48.4)
Yes169 (59.1)153 (60.0)16 (51.6)
BASELINE BARRIERS: if you would decide not to vaccinate, why would that be?
Need more information?0.40
(strongly) disagree98 (34.6)84 (33.3)14 (45.2)
neutral17 (6.0)15 (5.9)2 (6.4)
(strongly) agree168 (59.4)153 (60.7)15 (48.4)
Doubt the vaccine works?0.36
(strongly) disagree197 (70.1)174 (69.6)23 (74.2)
neutral24 (8.5)20 (8.0)4 (12.9)
(strongly) agree60 (21.3)56 (22.4)4 (12.9)
Fear of side effects?0.26
(strongly) disagree149 (52.5)129 (51.0)20 (64.5)
neutral27 (9.5)26 (10.31 (3.2)
(strongly) agree108 (38.0)98 (38.7)10 (32.3)
Fear of interference with fertility?0.43
(strongly) disagree171 (60.4)149 (59.1)22 (71.0)
neutral45 (15.9)41 (16.3)4 (12.9)
(strongly) agree67 (23.7)62 (24.6)5 (16.1)
Afraid of unsafe administration?0.07
(strongly) disagree203 (71.7)177 (70.2)26 (83.9)
neutral17 (6.0)14 (5.6)(9.7)
(strongly) agree63 (22.3)61 (24.2)2 (6.4)
It might encourage unsafe sex0.94
(strongly) disagree238 (84.7)212 (84.8)26 (83.9)
neutral23 (8.2)20 (8.0)3 (9.7)
(strongly) agree20 (7.1)18 (7.2)2 (6.4)
Daughter is too young for vaccine against an STI?0.91
(strongly) disagree250 (88.3)222 (88.1)28 (90.3)
neutral9 (3.2)8 (3.2)1 (3.2)
(strongly) agree24 (8.5)22 (8.7)2 (6.4)
Partner won’t approve?0.70
(strongly) disagree **** 221 (78.4)196 (78.1)25 (80.6)
neutral30 (10.6)28 (11.2)2 (6.4)
(strongly) agree31 (11.0)27 (10.8)4 (12.9)
Vaccination takes a lot of time0.75
(strongly) disagree275 (96.8)245 (96.8)30 (96.8)
neutral6 (2.1)5 (2.0)1 (3.2)
(strongly) agree3 (1.1)3 (1.2)0 (0.00)
Inconvenience of 3 doses needed0.08
(strongly) disagree265 (96.0)236 (96.3)29 (93.5)
neutral6 (2.2)6 (2.4)0 (0.0)
(strongly) agree5 (1.8)3 (1.2)2 (6.4)
BASELINE ACCEPTANCE
Would you vaccinate your daughter against cervical cancer?0.69
very unlikely6 (2.1)6 (2.3)0 (0.0)
unlikely3 (1.0)3 (1.2)0 (0.0)
neutral25 (8.7)21 (8.2)4 (12.9)
likely80 (27.9)73 (28.5)7 (22.6)
very likely173 (60.3)153 (59.8)20 (64.5)

IQR = interquartile range

*13+: those who studied in higher education i.e. college (middle level) and/or university

**housing: continuous variable constructed by scoring aspects of the living place: material of the roof, walls and floors, and toilet and water facilities

*** women were asked where they had lived for most of the time up to 12 years of age

**** includes participants without a relationship

Table 2

Bivariate logistic regression with acceptance and uptake of the HPV vaccine as outcomes.

VARIABLEBASELINE ACCEPTANCEUPTAKE
nAcceptance (%)AOR[95% CI]nUptake (%)AOR[95% CI]
BASELINE CHARACTERISTICS
Participant age at baseline2861.05* [1.01–1.08]2541.01[0.97–1.04]
Age of daughter at baseline2851.14[0.85–1.54]2531.03[0.86–1.23]
Years of education of participant2790.10[0.88–1.23]2471.05[0.99–1.11]
Housing2870.81[0.61–1.08]2551.12[0.74–1.70]
Marital status of participant287255
With partner188/217 (86.6)57/193 (29.5)
Without partner65/70 (92.9)0.53[0.15–1.84]22/62 (35.5)0.75[0.43–1.32]
Religion of participant285253
Protestant202/226 (89.4)58/203 (28.6)
Catholic41/46 (89.1)1.07[0.23–4.88]17/39 (43.6)1.92*[1.19–3.09]
Muslim8/13 (61.5)0.20[0.04–1.09]4/11 (36.4)1.42[0.48–4.18]
Origin of participant284253
Urban155/171 (90.6)56/153 (36.6)
Rural—outside Kenya96/113 (85.0)0.61[0.19–1.94]22/100 (22.0)0.48[0.21–1.10]
Ever heard of cervical cancer?286254
No—don’t know107/117 (91.4)24/102 (23.5)
Yes145/169 (85.8)0.55[0.22–1.37]55/152 (36.2)1.93*[1.16–3.19]
BASELINE BARRIERS: if you would decide not to vaccinate, why would that be?
Need for more information?2831.00[0.84–1.20]2511.02[0.89–1.17]
Doubt the vaccine works?2810.75* [0.59–0.97]2490.98[0.76–1.26]
Fear of side effect?2840.69* [0.52–0.91]2521.00[1.76–1.31]
Fear of interference with fertility?2830.71* [0.53–0.96]2510.94[0.71–1.25]
Afraid of unsafe administration (i.e. using unclean needles)2830.76** [0.64–0.91]2511.04[0.78–1.40]
It might encourage unsafe sex2820.80[0.53–1.20]2500.81[0.52–1.26]
Daughter is too young for vaccine against an STI?2830.54** [0.38–0.76]2510.94[0.61–1.43]
Partner won’t approve?° 2820.44*** [0.31–0.61]2500.87[0.68–1.09]
Vaccination takes a lot of time2840.51[0.24–1.12]2520.86[0.60–1.21]
Inconvenience: 3 doses needed2760.67[0.36–1.24]2440.94[0.57–1.55]
ACCEPTANCE—WELL-INFORMED
Would you vaccinate your daughter? (Baseline)255
neutral—(very) unlikely5/30 (16.7)-
(very) likely74/225 (32.9)2.57*[1.11–5.94]
Were you well-informed about the cervical cancer vaccination program? (at follow-up)235
No10/88 (11.4)-
Yes68/147 (46.3)6.37**[2.21–18.36]

AOR: adjusted odds ratio—CI: confidence interval

° participants without a relationship are included in category ‘strongly disagree’

* p<0.05

** p<0.01

*** p<0.001

Table 3

Multivariate logistic regression with acceptance and uptake of the HPV vaccine as outcomes.

ACCEPTANCE—AOR [95% CI]UPTAKE—AOR [95% CI]
Model 1Model 2Model 3Model 1Model 2Model 3Model 4
n = 270n = 278n = 280n = 239n = 246n = 247n = 227
ACCEPTANCE—WELL-INFORMED
Would you vaccinate your daughter? (at baseline)3.36
(very) likely (ref: neutr.–(very) unlikely) [0.80–14.1]
Were you well-informed about the vaccination program? (at follow-up)6.37**
Yes (ref: No) [2.24–18.1]
BASELINE CHARACTERISTICS
Age of participant at baseline1.06* 1.003
[1.00–1.12]nw[0.96–1.04]nw
Age of daughter at baseline1.051.088
[0.77–1.44]nw[0.86–1.37]nw
Years of education of participant0.981.051
[0.89–1.08]nw[0.97–1.14]nw
Housing0.90nw0.972
[0.64–1.26][0.60–1.56]nw
Marital status of participant
Without partner (ref: with partner) 0.560.689
[0.15–2.00]nw[0.37–1.29]nw
Religion of participant. (ref: protestant.)
Catholic1.351.416
[0.28–6.42][0.57–3.50]
Muslim0.078** 1.171
[0.02–0.38]nw[0.42–3.26]nw
Origin of participant
rural—outside Kenya (ref: urban)0.490.5460.48* 0.53*
[0.15–1.62]nw[0.21–1.42][0.23–0.99][0.29–0.97]
Ever heard of cervical cancer? (at baseline)0.430.461.610* 1.84* 2.07*
Yes (ref: No–don’t know) [0.17–1.11][0.17–1.30][1.09–2.38][1.04–3.26][1.18–3.63]
BARRIERS AT BASELINE
Need for more information1.210.99
[0.86–1.71]nw[0.83–1.18]nw
Barriers inherent to vaccination° 0.861.06
[0.56–1.33]nw[0.68–1.63]nw
It might encourage unsafe sex0.940.82
[0.57–1.53]nw[0.49–1.37]nw
Daughter is too young for vaccine against an STI?0.720.67* 0.99
[0.48–1.10][0.45–0.99][0.57–1.69]nw
Partner won’t approve?0.50** 0.47*** 0.890.830.99
[0.33–0.74][0.32–0.71][0.68–1.16][0.67–1.03][0.74–1.32]
Barriers related to time constraints°° 0.681.00
[0.27–1.69]nw[0.57–1.74]nw
Cons9.86103.60** 138.38*** 0.200.681.070.06*
F-statistic (p)410.3 (0.04)14.15 (0.01)13.93 (0.00)2.661 (0.44)0.304 (0.91)5.916 (0.02)4.443 (0.06)

Model 1: including baseline characteristics; model 2: including barriers perceived at baseline; model 3: including baseline characteristics and barriers obtained by stepwise backward regression—model 4: model 3 + acceptance and being well-informed about the HPV vaccination program

AOR: adjusted odds ratio—CI: confidence interval

°average of: doubt the vaccine works, fear of side effects and interference with fertility, and afraid of unsafe administration; alpha = 0.90

°° average of: vaccination takes a lot of time and 3 doses are inconvenient; alpha = 0.79

nw: not withheld in backward stepwise regression

* p<0.05

** p<0.01

*** p<0.00

IQR = interquartile range *13+: those who studied in higher education i.e. college (middle level) and/or university **housing: continuous variable constructed by scoring aspects of the living place: material of the roof, walls and floors, and toilet and water facilities *** women were asked where they had lived for most of the time up to 12 years of age **** includes participants without a relationship AOR: adjusted odds ratio—CI: confidence interval ° participants without a relationship are included in category ‘strongly disagree’ * p<0.05 ** p<0.01 *** p<0.001 Model 1: including baseline characteristics; model 2: including barriers perceived at baseline; model 3: including baseline characteristics and barriers obtained by stepwise backward regression—model 4: model 3 + acceptance and being well-informed about the HPV vaccination program AOR: adjusted odds ratio—CI: confidence interval °average of: doubt the vaccine works, fear of side effects and interference with fertility, and afraid of unsafe administration; alpha = 0.90 °° average of: vaccination takes a lot of time and 3 doses are inconvenient; alpha = 0.79 nw: not withheld in backward stepwise regression * p<0.05 ** p<0.01 *** p<0.00
  1 in total

1.  Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya.

Authors:  Heleen Vermandere; Violet Naanyu; Hillary Mabeya; Davy Vanden Broeck; Kristien Michielsen; Olivier Degomme
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.